CN104628547B - A kind of synthetic method of medicine intermediate difluoromethoxy based compound - Google Patents

A kind of synthetic method of medicine intermediate difluoromethoxy based compound Download PDF

Info

Publication number
CN104628547B
CN104628547B CN201510105183.8A CN201510105183A CN104628547B CN 104628547 B CN104628547 B CN 104628547B CN 201510105183 A CN201510105183 A CN 201510105183A CN 104628547 B CN104628547 B CN 104628547B
Authority
CN
China
Prior art keywords
compound
formula
solvent
synthetic method
organic ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510105183.8A
Other languages
Chinese (zh)
Other versions
CN104628547A (en
Inventor
王峰
李健
刘光合
朱俊丽
王全钦
曾庆云
崔猛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NANYANG TANWA PHARMACY CO., LTD.
Original Assignee
Nanyang Tanwa Pharmacy Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanyang Tanwa Pharmacy Co Ltd filed Critical Nanyang Tanwa Pharmacy Co Ltd
Priority to CN201510105183.8A priority Critical patent/CN104628547B/en
Publication of CN104628547A publication Critical patent/CN104628547A/en
Application granted granted Critical
Publication of CN104628547B publication Critical patent/CN104628547B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Abstract

The invention provides the synthetic method of difluoromethoxy based compound shown in a kind of following formula (I),Described method includes: in a solvent, and under catalyst, organic ligand and alkali exist, formula (II) compound and formula (III) compound react, thus obtaining formula (I) compound,Wherein, R is H, C1-C6Alkyl, benzyl, halogen or nitro, described method is by the mutually collaborative of suitable catalyst, organic ligand, alkali and solvent and/or combination, it is achieved thereby that the efficient difluoro-methoxy of reaction substrate, difluoro-methoxy substituted compound can be obtained with high yield, the brand-new synthetic method of such intermediate is provided for field of medicaments, it is the very valuable novel technological method of one, there is the prospect that is extremely widely applied.

Description

A kind of synthetic method of medicine intermediate difluoromethoxy based compound
Technical field
The present invention relates to the synthetic method of a kind of halogenated compound, relate more particularly to the synthetic method of a kind of difluoromethoxy based compound that can be used as medicine intermediate, belong to organic synthesis field and medicine intermediate synthesis field.
Background technology
Halo group is the elementary cell constituting and having bioactive multi-medicament compound, for instance generally all contain halo group in enzyme inhibitor, pesticide etc.
Specifically, at drug world, the nimodipine such as containing halo group is a kind of conventional calcium antagonist, the symptom such as it can be used for treating iron-deficient cerebrovascular, migraine, slight subarachnoid hemorrhage cause cerebral vasospasm, sudden deafness, hypertension; Roflumilast is then a kind of PDE-4 inhibitor, and it can be used for treating the symptoms such as serious COPD patient bronchitis.
As can be seen here, the preparation synthetic method containing the compound of halo group class formation is Important Problems organic, pharmaceutical synthesis field institute extensive concern, to the great meaning in the field such as drug manufacture, research and development. Also just because of such important function of halo group compound, the preparation method that people have developed the multiple compound containing halo group, for instance:
YossiZafrani etc. (" Diethylbromodifluoromethylphosphonate:ahighlyefficientan denvironmentallybenigndifluorocarbeneprecursor ", Tetrahedron, 2009,65,5278-5283) reporting a kind of difluoromethyl method of phenol compound, its reaction equation is as follows:
ZhengJi etc. (" Chlorodifluoromethylphenylsulfone:anovelnon-ozone-deplet ingsubstance-baseddifluorocarbenereagentforO-andN-difluo romethylations ", Chem.Comm., 2007,5147-5151) reporting a kind of difluoromethyl method of novel phenol compound, its reaction equation is as follows:
As mentioned above, although having reported for work in prior art, multiple compounds carries out Halogenated such as the method for difluoromethyl, but it is few that the difluoromethyl reagent used in these methods also exists kind, and it is many suitable in the difluoromethylization reaction of phenolic compound under alkali condition, these factors greatly limit the difluoromethyl process of other substrate, causes that it must first be converted into certain specific precursor in pharmaceutical synthesis and just can carry out follow-up difluoromethylization reaction.
In view of this, the present inventor is intended to the synthetic method developing a kind of medicine intermediate difluoromethoxy based compound, the method can realize the efficient difluoro-methoxy of reaction substrate, thus obtaining difluoro-methoxy substituted compound with high yield, the brand-new synthetic method of such intermediate is provided for field of medicaments, it is the very valuable novel technological method of one, there is the prospect that is extremely widely applied.
Summary of the invention
For many defects of above-mentioned existence, the present inventor, after having paid substantial amounts of creative work, proposes the synthetic method of a kind of difluoromethoxy based compound that can be used as medicine intermediate through further investigation.
Specifically, the invention provides the synthetic method of difluoromethoxy based compound shown in a kind of following formula (I),
Described method includes: in a solvent, and under catalyst, organic ligand and alkali exist, formula (II) compound and formula (III) compound react, thus obtaining formula (I) compound,
Wherein, R is H, C1-C6Alkyl, benzyl, halogen or nitro.
In the described synthetic method of the present invention, C1-C6Alkyl refers to the alkyl with 1-6 carbon atom, for instance can be methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, sec-butyl, isobutyl group, the tert-butyl group, n-pentyl, isopentyl, n-hexyl etc.
In the described synthetic method of the present invention, halogen can be fluorine, chlorine, bromine or iodine.
In the described synthetic method of the present invention, described catalyst is palladium acetylacetonate (Pd (acac)2), acid chloride (Pd (OAc)2), palladium trifluoroacetate (Pd (TFA)2), three (dibenzalacetone) two palladium (Pd2(dba)3), palladium sulfate, Palladous nitrate., dichloro diamino palladium (Pd (NH3)Cl2), (1,5-cyclo-octadiene) palladium chloride (PdCl2(cod) any in), it is most preferred that for (1,5-cyclo-octadiene) palladium chloride (PdCl2(cod))��
In the described synthetic method of the present invention, described organic ligand is phosphorus-containing ligand, and it is any one in following formula L1-L3:
It most preferably is L1.
In L2 or L3, Ph represents phenyl, and t-Bu represents the tert-butyl group.
In the described synthetic method of the present invention, described alkali is any one in Sodium ethylate, potassium tert-butoxide, sodium tert-butoxide, sodium carbonate, potassium carbonate, cesium carbonate, Feldalat NM etc., it is most preferred that for sodium tert-butoxide.
In the described synthetic method of the present invention, described solvent is any one in acetonitrile, N-Methyl pyrrolidone (NMP), dioxane, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), toluene, PEG400 (PEG-400), it is most preferred that for DMSO.
In the described synthetic method of the present invention, the consumption of described solvent is not particularly limited, and those skilled in the art may select suitable consumption, reacting balance is such as made to carry out, or post processing is prone to the amount carried out, and this belongs to ordinary skill in the art means, and this is no longer going to repeat them.
In the described synthetic method of the present invention, the mol ratio of described formula (II) compound and formula (III) compound is 1:1.5-2.5, for instance can be 1:1.5,1:2 or 1:2.5.
In the described synthetic method of the present invention, the mol ratio of described formula (II) compound and catalyst is 1:0.02-0.05, for instance can be 1:0.02,1:0.03,1:0.04 or 1:0.05.
In the described synthetic method of the present invention, the mol ratio of described formula (II) compound and alkali is 1:2-3, for instance can be 1:2,1:2.5 or 1:3.
In the described synthetic method of the present invention, the mol ratio of described formula (II) compound and organic ligand is 1:0.04-0.08, for instance can be 1:0.04,1:0.06 or 1:0.08.
In the described synthetic method of the present invention, reaction temperature is 60-90 DEG C, for instance can be 60 DEG C, 70 DEG C, 80 DEG C or 90 DEG C
In the described synthetic method of the present invention, the response time is 3-6 hour, for instance can be 3 hours, 4 hours, 5 hours or 6 hours.
In the described synthetic method of the present invention, react the post processing after terminating as follows: after completion of the reaction, naturally cool to room temperature, Enough Dl water is added in reaction system, it is sufficiently mixed, obtain mixed liquor, then extract 2-3 time with ether, merge organic facies, drying with anhydrous sodium sulfate, removal of solvent under reduced pressure, the silica gel column chromatography of residue 200-300 order is easily separated, wherein using volume ratio be 1:1.5-3 acetone and the mixed solvent of n-butyl alcohol as eluent, thus obtaining formula (I) compound.
As mentioned above; the described method of the present invention; by the selection of suitable catalyst, organic ligand, alkali and solvent and combination; thus obtain as the difluoromethoxy based compound of pharmaceutical intermediate, field can be synthesized in organic synthesis field and medicine intermediate and there is the prospect of industrialization widely, large-scale production using high yield.
Detailed description of the invention
Below by specific embodiment, the present invention is described in detail; but the purposes of these exemplary embodiments and purpose are only used for enumerating the present invention; not the real protection scope of the present invention is constituted any type of any restriction, more non-protection scope of the present invention is limited thereto.
Wherein, the organic ligand used is above-mentioned organic ligand.
Embodiment 1
Under room temperature, in the appropriate solvent DMSO in reaction vessel, add 100mmol formula (II) compound, 150mmol formula (III) compound, 2mmolPdCl2(cod), 4mmol organic ligand L1 and 200mmol sodium tert-butoxide, be then warming up to 60 DEG C under stirring, and reaction 6 hours at such a temperature.
After completion of the reaction, naturally cool to room temperature, in reaction system, add Enough Dl water, it is sufficiently mixed, obtain mixed liquor, then extract 2-3 time with ether, merge organic facies, dry with anhydrous sodium sulfate, removal of solvent under reduced pressure, the silica gel column chromatography of residue 200-300 order is easily separated, wherein using volume ratio be 1:1.5 acetone and the mixed solvent of n-butyl alcohol as eluent, thus obtaining above formula (I) compound, yield is 98.5%.
1H-NMR(400MHz,CDCl3) ��: 6.62 (t, J=73.5Hz, 1H), 2.65 (t, J=6.0Hz, 2H), 2.44 (t, J=6.6Hz, 2H), 2.07-1.95 (m, 2H), 1.73 (s, 3H).
MSm/z:177 (M+1,100).
Embodiment 2
Under room temperature, in the appropriate solvent DMSO in reaction vessel, add 100mmol formula (II) compound, 250mmol formula (III) compound, 5mmolPdCl2(cod), 6mmol organic ligand L1 and 250mmol sodium tert-butoxide, be then warming up to 80 DEG C under stirring, and reaction 5 hours at such a temperature.
After completion of the reaction, naturally cool to room temperature, in reaction system, add Enough Dl water, it is sufficiently mixed, obtain mixed liquor, then extract 2-3 time with ether, merge organic facies, dry with anhydrous sodium sulfate, removal of solvent under reduced pressure, the silica gel column chromatography of residue 200-300 order is easily separated, wherein using volume ratio be 1:2.5 acetone and the mixed solvent of n-butyl alcohol as eluent, thus obtaining above formula (I) compound, yield is 98.2%.
1H-NMR(400MHz,CDCl3) ��: 6.47 (t, J=72.0Hz, 1H), 5.44 (s, 1H), 2.52-2.33 (m, 2H), 2.16 (m, 2H), 2.01 (m, 1H), 1.08 (d, J=6.1Hz, 3H).
MSm/z:176 (M+1,100).
Embodiment 3
Under room temperature, in the appropriate solvent DMSO in reaction vessel, add 100mmol formula (II) compound, 200mmol formula (III) compound, 4mmolPdCl2(cod), 8mmol organic ligand L1 and 300mmol sodium tert-butoxide, be then warming up to 90 DEG C under stirring, and reaction 3 hours at such a temperature.
After completion of the reaction, naturally cool to room temperature, in reaction system, add Enough Dl water, it is sufficiently mixed, obtain mixed liquor, then extract 2-3 time with ether, merge organic facies, dry with anhydrous sodium sulfate, removal of solvent under reduced pressure, the silica gel column chromatography of residue 200-300 order is easily separated, wherein using volume ratio be 1:3 acetone and the mixed solvent of n-butyl alcohol as eluent, thus obtaining above formula (I) compound, yield is 98.6%.
1H-NMR(400MHz,CDCl3) ��: 7.26-7.13 (m, 5H), 6.58 (t, J=73.3Hz, 1H), 3.69 (s, 2H), 2.67 (t, J=6.1Hz, 2H), 2.46-2.38 (m, 2H), 2.15-1.97 (m, 2H).
MSm/z:252 (M+1,100).
Embodiment 4-24: the investigation of catalyst
Embodiment 4-6: respectively by the PdCl in embodiment 1-32(cod) Pd (acac) is replaced with2, other operation is all constant, and implements embodiment 4-6.
Embodiment 7-9: respectively by the PdCl in embodiment 1-32(cod) Pd (OAc) is replaced with2, other operation is all constant, and implements embodiment 7-9.
Embodiment 10-12: respectively by the PdCl in embodiment 1-32(cod) Pd (TFA) is replaced with2, other operation is all constant, and implements embodiment 10-12.
Embodiment 13-15: respectively by the PdCl in embodiment 1-32(cod) Pd is replaced with2(dba)3, other operation is all constant, and implements embodiment 13-15.
Embodiment 16-18: respectively by the PdCl in embodiment 1-32(cod) replacing with palladium sulfate, other operation is all constant, and implements embodiment 16-18.
Embodiment 19-21: respectively by the PdCl in embodiment 1-32(cod) replacing with Palladous nitrate., other operation is all constant, and implements embodiment 19-21.
Embodiment 22-24: respectively by the PdCl in embodiment 1-32(cod) Pd (NH is replaced with3)Cl2, other operation is all constant, and implements embodiment 22-24.
Concrete outcome is shown in table 1 below.
Table 1: the impact of catalyst
From upper table 1, when using other palladium catalyst, all causing that productivity significantly reduces, this proves PdCl2(cod) there is best catalytic effect.
Embodiment 25-33: the investigation of organic ligand
Embodiment 25-27: respectively the phosphorus-containing ligand L1 in embodiment 1-3 is replaced with L2, other operation is all constant, and implements embodiment 25-27.
Embodiment 28-30: respectively the phosphorus-containing ligand L1 in embodiment 1-3 is replaced with L3, other operation is all constant, and implements embodiment 28-30.
Embodiment 31-33: respectively the phosphorus-containing ligand L1 in embodiment 1-3 is replaced with triphenylphosphine, other operation is all constant, and implements embodiment 31-33.
Concrete outcome is shown in table 2 below.
Table 2: the impact of phosphorus-containing ligand
From upper table 2, when using other phosphorus-containing ligand, all causing that productivity significantly reduces, even if using the triphenylphosphine very similar with L1, its productivity also significantly reduces, and thus demonstrates L1 and has best concerted catalysis effect.
Embodiment 34-39: the investigation of alkali
Except adopting different alkali, being carried out example 34-39 with the same way of embodiment 1-3 respectively, used alkali, corresponding relation and products collection efficiency are shown in table 3 below.
Table 3: the impact of alkali
From upper table 3, the kind of alkali has significant impact for final result, and wherein sodium tert-butoxide has best effect, even if the potassium tert-butoxide very similar with it, its productivity also has significant reduction (being reduced to 88.4% by 98.2%).
Embodiment 40-45: the investigation of solvent
Except adopting different solvents, being carried out example 40-45 with the same way of embodiment 1-3 respectively, used solvent, corresponding relation and products collection efficiency are shown in table 4 below.
Table 4: the impact of solvent
From upper table 4, the kind of solvent has a degree of impact for final result, and wherein DMSO has a best solvent effect, and all decreases to some degree of other solvent.
As mentioned above, the invention provides the synthetic method of a kind of difluoromethoxy based compound that can be used as medicine intermediate, the method is by the mutually collaborative of suitable catalyst, organic ligand, alkali and solvent and/or combination, it is achieved thereby that the efficient difluoro-methoxy of reaction substrate, difluoro-methoxy substituted compound can be obtained with high yield, provide the brand-new synthetic method of such intermediate for field of medicaments, be the very valuable novel technological method of one, there is the prospect that is extremely widely applied.
Should be appreciated that the purposes of these embodiments is merely to illustrate the present invention and is not intended to limit the scope of the invention. In addition; it is also contemplated that; after the technology contents having read the present invention, the present invention can be made various change, amendment and/or modification by those skilled in the art, and all these equivalent form of value falls within the application appended claims protection defined equally.

Claims (9)

1. a synthetic method for difluoromethoxy based compound shown in following formula (I),
Described method includes: in a solvent, and under catalyst, organic ligand and alkali exist, formula (II) compound and formula (III) compound react, thus obtaining formula (I) compound,
Wherein, R is H, C1-C6Alkyl, benzyl, halogen or nitro;
Described catalyst is (1,5-cyclo-octadiene) palladium chloride;
Described organic ligand is phosphorus-containing ligand, and it is any one in following formula L1-L3:
Described alkali is sodium tert-butoxide.
2. method according to claim 1, it is characterised in that: described organic ligand is L1.
3. method according to claim 1 and 2, it is characterised in that: described solvent is any one in acetonitrile, N-Methyl pyrrolidone, dioxane, dimethyl sulfoxide, dimethylformamide, toluene, dichloromethane.
4. method according to claim 3, it is characterised in that: described solvent is dimethyl sulfoxide.
5. method according to claim 1 and 2, it is characterised in that: the mol ratio of described formula (II) compound and formula (III) compound is 1:1.5-2.5.
6. method according to claim 1 and 2, it is characterised in that: the mol ratio of described formula (II) compound and catalyst is 1:0.02-0.05.
7. method according to claim 1 and 2, it is characterised in that: the mol ratio of described formula (II) compound and alkali is 1:2-3.
8. method according to claim 1 and 2, it is characterised in that: the mol ratio of described formula (II) compound and organic ligand is 1:0.04-0.08.
9. method according to claim 1 and 2, it is characterised in that: reaction temperature is 60-90 DEG C; Response time is 3-6 hour.
CN201510105183.8A 2015-03-11 2015-03-11 A kind of synthetic method of medicine intermediate difluoromethoxy based compound Active CN104628547B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510105183.8A CN104628547B (en) 2015-03-11 2015-03-11 A kind of synthetic method of medicine intermediate difluoromethoxy based compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510105183.8A CN104628547B (en) 2015-03-11 2015-03-11 A kind of synthetic method of medicine intermediate difluoromethoxy based compound

Publications (2)

Publication Number Publication Date
CN104628547A CN104628547A (en) 2015-05-20
CN104628547B true CN104628547B (en) 2016-06-08

Family

ID=53207844

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510105183.8A Active CN104628547B (en) 2015-03-11 2015-03-11 A kind of synthetic method of medicine intermediate difluoromethoxy based compound

Country Status (1)

Country Link
CN (1) CN104628547B (en)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Guokai Liu.Selective O‑Difluoromethylation of 1,3-Diones by Bromodifluoromethylating Reagents.《Organic Letters》.2013,第15卷(第5期),1044-1047. *
Xiaoxi Lin et al..A new method for the synthesis of difluoromethyl enol ethers by O-difluoromethylation of 1,3-diones with ClCF2CO2Et.《Organic & Biomolecular Chemistry》.2015,第13卷3432-3437. *

Also Published As

Publication number Publication date
CN104628547A (en) 2015-05-20

Similar Documents

Publication Publication Date Title
EP3712130B1 (en) Method for synthesis of roxadustat and intermediate compounds thereof
CN104844399B (en) A kind of method synthesizing 2-fluorophenol compound
JP2008063278A (en) Method for producing 1-pyridin-4-yl-indole
CN102875537A (en) Novel preparation method of antithrombosis medicine
CN103601645B (en) The preparation method of 1-(phenethyl amino) propane-2-alcohol compound or its salt
KR102132087B1 (en) Method for preparing azoxystrobin
CN101302207B (en) Preparation of 3-o-alkyl-5,6-o-(1-methyl ethylidine)-l-ascorbic acid and preparation of 5,6-o-(1- methyl ethylidine)-l- ascorbic acid
CN108546253B (en) Method for multi-step synthesis of 2-benzyl-1, 5-dihydrobenzo [ e ] [1,4] oxazepine
US7595417B2 (en) Cyanation of aromatic halides
CN105985258B (en) A kind of Preparation Method And Their Intermediate of benzamide compounds
CN107118215B (en) A kind of preparation method for treating breast cancer medicines Rui Boxini intermediate
CN104311485B (en) A kind of preparation method treating leukemic medicine bosutinib
CN110845401B (en) Synthesis method of 2-fluoro-3, 6-dihydroxypyridine
CN104628547B (en) A kind of synthetic method of medicine intermediate difluoromethoxy based compound
CN104649934B (en) A kind of synthetic method of medicine intermediate trifluoromethyl substituted arene compounds
CN101791574A (en) Catalyst loaded with chiral imidazolium and preparation method thereof
CN104803912B (en) A kind of synthetic method of medicine intermediate quinoline compound
CN105085320B (en) Synthesis method of dicyano substituted biphenyl compounds
CN110028448B (en) Preparation method of 3-hydroxy-2,3-dihydroisoquinoline-1, 4-diketone compound
CN108191737B (en) Process for producing N- (2-methylthiophenyl) isoindole-1, 3-dione compound
CN106866608B (en) A kind of preparation method of fluoro -3,4- dihydrocoumarin derivative
CN106187672A (en) The synthetic method of triarylbenzenes compounds between a kind of pharmaceutical intermediate
CN106866558B (en) Acyl group triazole compound and its preparation method and application
CN109400507A (en) The synthesis of Ailamode intermediate impurities
CN104744391B (en) The synthetic method of a kind of medicine intermediate azoles alkyl compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
CB03 Change of inventor or designer information

Inventor after: Yang Lin

Inventor before: He Siwei

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20160429

Address after: Tianhe District Tong East Road Guangzhou city Guangdong province 510665 B-101 No. 5, room B-118

Applicant after: Guangdong Gaohang Intellectual Property Operation Co., Ltd.

Address before: Hangzhou City, Zhejiang province 311605 Jiande Sandu town and village Changshan Panlong No. 26

Applicant before: He Siwei

C41 Transfer of patent application or patent right or utility model
CB03 Change of inventor or designer information

Inventor after: Wang Feng

Inventor after: Li Jian

Inventor after: Liu Guanghe

Inventor after: Zhu Junli

Inventor after: Wang Quanqin

Inventor after: Zeng Qingyun

Inventor after: Cui Meng

Inventor before: Yang Lin

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20160512

Address after: 473039 Wang Cun Township, Wolong District, Henan, Nanyang

Applicant after: NANYANG TANWA PHARMACY CO., LTD.

Address before: Tianhe District Tong East Road Guangzhou city Guangdong province 510665 B-101 No. 5, room B-118

Applicant before: Guangdong Gaohang Intellectual Property Operation Co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant